» Articles » PMID: 16963547

Chronic Obstructive Pulmonary Disease, Risk Factors, and Outcome Trials: Comparisons with Cardiovascular Disease

Overview
Specialty Pulmonary Medicine
Date 2006 Sep 12
PMID 16963547
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic obstructive pulmonary disease (COPD) is a major health problem and now ranks fifth in terms of the global burden of disease. Although COPD is a disease that is characterized by progressive respiratory symptoms and functional decline, exacerbations pose the greatest risk for morbidity and early mortality, have a dramatic effect on quality of life, and are the most significant source of health care expenditure. To improve survival and reduce costs, it is critical to develop effective programs designed to reduce the frequency and severity of exacerbations for these patients. With limited health care resources, efficient and effective management of COPD ideally involves identifying and focusing efforts on individuals at particular risk. In the development of an appropriate multimodal strategy, lessons could be learned from the evolution of guidelines and management of cardiovascular disease, in particular heart failure, which has many parallels with COPD in terms of prevalence, prognosis, and impact on patient quality of life. There is a need for large prospective trials in COPD, based on hard clinical outcomes such as death, which, together with physician and patient education, will help to drive improvements in clinical management.

Citing Articles

Factors contributing to hospitalization expenditures for patients with COPD in Yunnan Province, China: a path analysis.

Wen A, Meng J, Luo G, Wen G, Cui W, Tang S BMC Health Serv Res. 2024; 24(1):1496.

PMID: 39609664 PMC: 11603990. DOI: 10.1186/s12913-024-11874-4.


Heart Rate Variability on 10-Second Electrocardiogram and Risk of Acute Exacerbation of COPD: A Secondary Analysis of the BLOCK COPD Trial.

MacDonald D, Mkorombindo T, Ling S, Adabag S, Casaburi R, Connett J Chronic Obstr Pulm Dis. 2022; 9(2):226-236.

PMID: 35403415 PMC: 9166329. DOI: 10.15326/jcopdf.2021.0264.


Cardiovascular events and all-cause mortality in patients with chronic obstructive pulmonary disease using olodaterol and other long-acting beta2-agonists.

Rebordosa C, Farkas D, Montonen J, Laugesen K, Voss F, Aguado J Pharmacoepidemiol Drug Saf. 2022; 31(8):827-839.

PMID: 35320605 PMC: 9545725. DOI: 10.1002/pds.5432.


Association Between a History of Nontyphoidal and the Risk of Systemic Lupus Erythematosus: A Population-Based, Case-Control Study.

Tu T, Yeh C, Hung Y, Chang R, Chen H, Cheng-Chung Wei J Front Immunol. 2021; 12:725996.

PMID: 34887848 PMC: 8650632. DOI: 10.3389/fimmu.2021.725996.


Factors associated with inpatient length of stay among hospitalised patients with chronic obstructive pulmonary disease, China, 2016-2017: a retrospective study.

Dong F, Huang K, Ren X, Qumu S, Niu H, Wang Y BMJ Open. 2021; 11(2):e040560.

PMID: 33550232 PMC: 7925858. DOI: 10.1136/bmjopen-2020-040560.